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Recently, the National Cancer Institute published a comprehensive monograph on multiple
primary cancers in Connecticut and Denmark [1]. This paper summarizes some of the
observations made on the Connecticut population. Data compiled by the Connecticut Tumor
Registry have extended our knowledge about the patterns ofmultiple primary cancers, especially
among long-term survivors ofcancer and among patients with relatively rare tumors about which
little information currently exists. When compared with the general Connecticut population,
cancer patients had a 31 percent (RR = 1.31) increased risk ofdeveloping a second cancer and a
23 percent (RR = 1.23) elevated risk ofsecond cancer at a different site from the first. Common
environmental exposures seemed responsible for the excess occurrence of many second cancers,
particularly those related to cigarette smoking, alcohol consumption, or both. For example,
persons with epithelial cancers of the lung, larynx, esophagus, buccal cavity, and pharynx were
particularly prone to develop new cancers in the same or contiguous tissue throughout their
lifetimes. Cancers of the colon, uterine corpus, breast, and ovary frequently occurred together,
suggesting underlying hormonal or dietary influences. Only patients with prostate cancer were at
significantly low risk for second cancer development; this might be an artifact of case finding,
since advanced age at initial diagnosis was generally associated with an underascertainment of
second cancers. Radiotherapy may have caused rectal and other cancer among patients with
cancers of the female genital tract, and leukemia among patients with uterine corpus cancer.
Chemotherapy with alkylating agents probably contributed to the excess of acute non-
lymphocytic leukemia following multiple myeloma or cancers of the breast and ovary. Genetic
susceptibility seemed to explain some tumor complexes, such as the multiple occurrences of
cutaneous melanoma and the excess of bone cancer following retinoblastoma. Research into
multiple cancer syndromes should enhance our understanding of carcinogenic factors and
mechanisms and the development ofstrategies for cancer prevention and control.
INTRODUCTION
A comprehensive monograph on the riskofdeveloping multiple primary cancers has
recently been prepared by the National Cancer Institute in conjunction with the
Connecticut Tumor Registry and the Danish Cancer Registry [1]. The reader
interested in more details on the historical review, subjects and methods, results, and
discussion is referred to this volume. Our paper attempts to provide an overview ofthe
major findings with emphasis on results ofinterest to the Connecticut community. This
monograph is the source ofmaterial for the sections following.
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SUMMARY OF MONOGRAPH FINDINGS
All First Cancers Combined
Data from 253,536 Connecticut patients diagnosed with an invasive cancer during
1935 to 1982 who survived at least two months without developing a simultaneous
primary were combined so that their collective risk ofsecond primary cancer over time
could be examined [2]. More than 1,100,000 person-years offollow-up were accumu-
lated for an average of 4.5 years per person. Both the first and second cancers were
microscopically confirmed 88 percent ofthe time. A new primary neoplasm developed
in 16,727 (6.6 percent) patients, whereas 12,797 second cancers were expected on the
basis ofrates from the general Connecticut population. Thus, patients with one cancer
had 1.31 times the risk [95 percent confidence interval (CI) = 1.29-1.33] ofdevelop-
ing a new independent primary compared with Connecticut residents without cancer.
This relative risk (RR) is remarkably similar to the 1.29 risk estimate reported from
Schoenberg's earlier Connecticut study (1935-1964), although almost twenty addi-
tional yearsofcancerdiagnoses and follow-up wereadded to the Connecticut data base
[3]. The riskofdeveloping a second cancer was 14.7 per 1,000 persons peryear, and the
excess risk, i.e., after removing the expected incidence based on population rates, was
3.5 per 1,000 persons per year.
Connecticut residents with cancer remained at increased risk for a new malignant
neoplasm throughout their lifetimes. Moreover, the risk increased from 1.29 during
their first twenty years of follow-up to 1.49 for the 12,515 individuals surviving more
than twenty years. Thirty-year survivors (2,218 patients, mostly female) continued to
develop new second cancers at a high rate (RR = 1.45). Overall, 3,930 excess cancers
developed over what would normally be expected in this population; 1,242 excess
cancers (4.6 per 1,000 per year) developed after ten or more years offollow-up.
Females were more likely than males to develop a second cancer: RR = 1.42 versus
1.19 (Fig. 1). However, this difference was only apparent in the first twenty years of
survival. Second cancers of the breast and gynecologic organs were responsible for a
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FIG. 1. Observed/expected ratios for all second cancers by time since diagnosis of any initial primary
cancer and by sex. 95 percent confidence intervals are presented.
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TABLE 1
Etiologic Factors Involved in Multiple Primary Cancers*
Etiologic factors Associated cancer sites
Environmental, endocrine, or
genetic riskfactors
Tobacco or alcohol Cancers ofthe respiratory and upper digestive tracts
consumption, or both
Endocrine or dietary Multicentric cancers ofthecolon; bilateral breast
factors, or both cancer; and clusters ofcancers ofthe breast, uter-
ine corpus, ovary, and colon
Genetic predisposition Retinoblastoma and osteosarcoma, among others
Treatment effects
Radiation Cancer ofthe rectum following cervical cancer,
among others
Chemotherapy ANLL following Hodgkin's disease, NHL, multiple
myeloma, and cancers ofthe ovary, breast, gastro-
intestinal tract, and lung, and childhood cancers
Hormones Cancer ofuterine corpus following breast cancer
Immunologicdefects Melanoma following chronic lymphocytic leukemia,
among others
*Slightly modified from text-Table 1 [4]
large part ofthe sex differential in risk. Other sites for which the RR ofsecond cancer
was notably higher in women than men included the rectum (1.3 vs. 1.0), lung (1.6 vs.
1.3), bladder (1.4 vs. 1.2), eye (1.8 vs. 1.1), and endocrine glands (2.9 vs. 1.4). The
higher RR among women with second cancers of smoking-related sites, such as the
lung, may bedue to thelower baseline incidence rates forthese cancers among females
than among males, coupled with the higher frequency of cigarette smoking among
cancer patients compared with the general population. Only two second cancer sites
had substantially higher risks for men than for women: thyroid (2.2 vs. 1.5) and liver
(1.3 vs. 1.0). The thyroid cancer difference was primarily due to the high risk observed
for men within one year ofdiagnosis ofthe initial primary.
Etiologic Hypotheses
The introductory chapter on multiple primary cancers in the NCI monograph [4]
discussed a number ofobservations previously reported in other studies. The etiologic
hypotheses are listed in Table 1 and are further discussed below, emphasizing the new
findings from the current investigation.
Tobacco and Alcohol Table 2 presents recent findings from Connecticut
suggesting the possible influence ofcigarette smoking and/or alcohol consumption on
the development ofboth first and second cancers [5]. Figure 2 depicts the high risk of
developing a new cancer ofthe oral cavity following a primary cancer ofthe lung over
time and further exemplifies the continuing influence of past or current exposures on
cancer risk. Tobacco smoking is clearly one ofthe major causes ofsecond cancers as it
is for the first cancers [6]. Previous studies ofsecond tumors among patients with lung
cancer have found excess cancers ofthe oral cavity, larynx, bladder, cervix, and other
tobacco-related sites [3,7,8,9,10,11]. The combined effects of tobacco and alcohol
account largely for the constellation of multiple cancers arising in the oral cavity,
larynx, and esophagus. The risks of developing a second tobacco- or alcohol-related
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TABLE 2
Examples of Observed-to-Expected Ratios of Certain Cancers for Which the First and Second Cancer
Might Be Associated with Cigarette Smoking and/or Alcohol Consumption
No.
First Cancer Second Cancer Second Cancers RR*
Lung Lung 110 1.5
Oral cavity** 46 2.5
Larynx Lung 178 3.2
Oral cavity 40 2.7
Esophagus Oral cavity 11 7.8
*O/E ratios for second primaries withp < .05
**ICD-O 140-149
cancer have been linked mainly to the habits prevailing before the onset of the initial
cancer, although continued smoking and drinking may enhance the risk [10]. Clearly,
it is prudent to advise patients to stop or curtail their consumption of alcohol and
cigarettes.
Endocrine andDietary Factors Table 3 presents recent findings from Connecti-
cut confirming the significant associations previously reported for cancers ofthe colon,
breast, uterine corpus, and ovary [12,13,14]. The bidirectional nature of these
associations is remarkable. Figure 3 indicates the elevated risk of a second cancer of
the female breast over time following an initial primary breast cancer. These high risks
could be associated with hormonal, dietary, and/or genetic influences, as well as
heightened medical surveillance. The constellation of multiple cancers of the breast,
uterine corpus, ovary, and colon has long intrigued investigators [15,16,17,18,19,20].
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TABLE 3
Examples of Observed-to-Expected Ratios of Certain Cancers for Which the First and Second
Cancers Might Be Associated with Hormonal and/or Dietary Factors
No.
First Cancer Second Cancer Second Cancers RR*
Colon Breast 232 1.2
Uterine corpus 80 1.7
Ovary 77 2.4
Breast Colon 411 1.2
Uterine corpus 227 1.4
Ovary 183 1.7
Corpus uteri Colon 192 1.4
Breast 297 1.3
Ovary Colon 63 2.0
Uterine corpus 26 1.6
Breast 87 1.4
*O/E ratios for second primaries withp < .05
Because reproductive factors (e.g., nulliparity) and dietary habits (e.g., high fat
intake) appear involved in these cancers, some think that nutritional and hormonal
interactions may contribute to the development of multiple primaries of these sites
[21,22].
Genetic Predisposition Table 4 presents recent findings from Connecticut
suggesting the possible influence ofgenetic predisposition on the development of some
multicentric cancers and also on the high risk of osteosarcoma after retinoblastoma
[2,23]. Although it is unlikely that hereditary cancers contribute substantially to the
overall incidence of second tumors among cancer patients, some complexes of tumors
result from genetic factors. The association between bilateral retinoblastoma and
osteosarcoma illustrates the influence of hereditary factors [24]. Genetic predisposi-
tion may also contribute to multicentric cancers arising in the colon and bilateral
breast cancer, which are associated with a tendency to familial aggregation. Certain
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TABLE 4
Examples of Observed-to-Expected Ratios of Certain Second Cancers for Which the First and Second
Cancers Might Be Linked Due to a Genetic Predisposition, Including the Tendency for Multicentric
Tumors to Develop
(Ratios for other multifocal tumors are also listed for completeness.)
No.
First Cancer Second Cancer Second Cancers RR*
Possible Genetic Predisposition
Breast Breast 1,927 3.0
Colon Colon 506 2.1
Melanoma Melanoma 30 8.5
Thyroid Thyroid 5 4.7
Eye Bone 3 35.7
Other Multifocal Tumors
Mouth Mouth 50 25.1
Lung Lung 110 1.5
Kidney Kidney 16 2.9
Testis Testis 6 11.2
Connective tissue Connective tissue 4 6.3
*O/E ratios for second primaries with p < .05
families appear prone to developing cancer of diverse sites (e.g., adenocarcinomas of
colon and endometrium; soft tissue sarcomas and breast cancer), with multiple
primaries occurring at an early age in some family members [25]. Genetic-
environmental interactions are illustrated by the high risk of radiogenic sarcomas in
hereditary forms ofretinoblastoma and in the cancer family syndrome described by Li
and Fraumeni [26].
TABLE 5
Examples of Observed-to-Expected Ratios of Certain Cancers for Which the Second Cancer Might Be
Associated with Prior Radiotherapy for the Initial Primary Cancer
No.
First Cancer Second Cancer Second Cancers RR*
Cervix Kidney 11 3.4**
Bladder 28 5.0**
Rectum 36 3.0**
Ovary 16 1.8**
Breast 36 0.7
Uterine corpus Rectum 22 2.0**
ANLL 10 2.4
Ovary Colon 11 2.6**
Rectum 6 3.5**
Bladder 6 7.2**
Breast Lung 24 2.8**
Hodgkin's disease Breast 8 3.0**
Thyroid 4 6.7
Oral cavity 7 3.1
Lung 12 5.5**
Bone Connective tissue 2 16.4
*O/E ratios for second primaries withp < .05
**10+ year survivors
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TABLE 6
Examples of Observed-to-Expected Ratios for Certain Cancers for Which the Second Cancer Might
Be Related to Chemotherapy for the Initial Primary Cancer
No.
First Cancer Second Cancer Second Cancers RR*
Multiple myeloma ANLL 9 16.0
Ovary ANLL 7 43.0
*O/E ratios for second primaries withp < .05
Multifocal Origins Other than genetic predisposition, possible reasons for the
high risk associated with developing a second tumor of the same site or in contiguous
tissue (Table 4) include the influence of common etiologic factors (such as cigarette
smoking, diet, hormonal factors), heightened medical surveillance, and mistaken
metastases. It should be noted that for paired organs such as the breast, testis, and
kidney, risk estimates for developing a second tumor of the contralateral organ are
likely underestimates by a factor approaching two. This is because rates from the
general population are based upon persons having both paired organs intact, whereas
the patients with cancer of these sites usually have the cancerous organ removed
surgically and thus have only one contralateral organ at risk for subsequent cancer
development.
Treatment Effects Tables 5 and 6 present recent findings from Connecticut
suggesting the possible influence of radiotherapy and chemotherapy on the develop-
ment of certain second cancers. The high risks of cancers of the breast, thyroid, oral
cavity, and lung following Hodgkin's disease treatment (Table 5) are noteworthy since
these sites can receive intense radiation exposures. Figure 4 indicates the high risk of
bladder cancer possibly associated with radiotherapy for cervical cancer [14], and Fig.
5 indicates the high risk of acute non-lymphocytic-leukemia (ANLL) that appears
linked to chemotherapy for ovarian cancer [2,27]. Clearly, in the absence of such
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treatment for ovarian cancer, patient survival is often dismal, but in other settings
where chemotherapy is given in an adjuvant fashion, careful assessment of the risks
and benefits is essential. Interestingly, ANLL was not found to be increased following
Hodgkin's disease or non-Hodgkin's lymphoma (NHL). These negative findings,
however, were not unexpected, since tumor registry coding practices in the past were
such that ANLL would not be recorded as a separate independent second cancer when
the first cancer was a malignant lymphoma [28].
During the last twenty years, the number of cancer patients treated with radiation
and chemotherapy has increased, and the study oftherapy-related second cancers has
become more important [28,29]. Children treated with radiotherapy have been
reported at high risk of second cancers [30,31], although the risk of subsequent
leukemia does not seem significantly affected by radiation [32]. Cervical cancer
patients exposed to high-dose radiotherapy are prone to develop cancers ofthe rectum
and other sites within the pelvis that receive substantial radiation exposures [33]. In
this group, a significantly low rate of breast cancer appears due, in large part, to a
protective effect resulting from ovarian ablation. Radiotherapy increases the risk of
leukemia following relatively low-dose total body irradiation for NHL [34] and of
osteosarcomas following high-dose radiotherapy for Ewing's sarcoma [35] and retino-
blastoma [24]. Soft tissue sarcomas also appear to be a rare consequence of high-dose
TABLE 7
Observed-to-Expected Ratios of Certain Cancers for Which the Second Cancer Might Be Related to
Immunosuppression Associated with the Initial Primary Cancer and/or Treatment for the Initial
Primary Cancer
No.
First Cancer Second Cancer Second Cancers RR*
Leukemia Melanoma 5 3.7**
NHL Melanoma 6 3.1 **
NHL Stomach 20 1.7
*O/E ratios for second primaries with p < .05
**Males only
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radiotherapy for cancer [36]. Estrogen therapy and ovarian radiotherapy for breast
cancer have both been related to an increased risk of endometrial cancer [37,38].
Alkylating agents have been associated with extremely high risks ofsubsequent ANLL
following treatment for ovarian cancer [27], gastrointestinal cancers [39], breast
cancer [40], multiple myeloma [41], lung cancer [42], Hodgkin's disease [43,44],
NHL [34], and childhood cancers [31]. Cyclophosphamide, an alkylating agent, has
been associated with bladder cancer as well as chronic cystitis [45].
Immunologic Defects Table 7 presents recent data from Connecticut suggest-
ing the role of immunosuppression in the development of second skin cancers [46].
Figure 6 indicates the high risk ofstomach cancer after NHL due to radiation therapy
or to immunosuppression. Stomach cancer is known to complicate certain states of
immunodeficiency [47,48], and the immune defects which accompany lymphoma may
be aggravated by radiation or chemotherapy [49]. Certain cancers are thought to be
complicated by immunodeficiency states which appear to predispose to certain
cancers. For example, skin cancers (melanoma and non-melanoma) have occurred
excessively after chronic lymphocytic leukemia [50]. An increase of NHL following
Hodgkin's disease has been linked to the immunosuppressive effects of combination
chemotherapy and radiotherapy [51]. Various cancers, in particular NHL, have
occurred excessively in organ transplant recipients treated with immunosuppressants
[48].
Obscure Mechanisms A number of associations between cancers have been
reported without apparent explanation. For example, cancers ofthe breast and salivary
gland haveclustered in several [52,53,54] but not all studies [55,56], and leukemia has
occurred excessively following cancer of the testis [3], but the mechanisms are
uncertain. Table 8 presents some tumor relationships from Connecticut for which no
explanation appears obvious [2]. Leukemia, for example, has been found in excess
following cancers ofthe prostate, testis, and lip. Due tothemultiple comparisons made,
chance cannot be easily ruled out; however, some of the associations might provide
leads for new etiologic hypotheses.
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TABLE 8
Examples of Observed-to-Expected Ratios of Certain Cancers for Which a Possible Explanation Is
Not Readily Available
No.
First Cancer Second Cancer Second Cancers RR*
Leukemia Lung 54 2.1
Female genital 3 0.3
Non-Hodgkin's lymphoma Brain 9 3.1
Thyroid Kidney 10 4.8
Eye Lung 14 2.5
Prostate Leukemia 64 1.3
Testis Pancreas 6 3.9
Leukemia 8 5.2
Breast Multiple myeloma 14 0.5
Rectum Stomach 34 0.7
Lip Leukemia 17 2.1
*O/E ratios for second primaries withp < .05
CAUTIONS IN INTERPRETATION
The results from our analyses of multiple primary cancer must be interpreted in
light of changes in medical care and reporting practices that occurred over the many
years of cancer registration in Connecticut [4]. Risk factors common to multiple
cancer have also varied over time, as illustrated by the increasing proportion of
smokers among women in our population [57]. Intense medical surveillance and
conditions peculiar to the evaluation of second cancers (e.g., misclassified metastases
and autopsy diagnoses) may also affect the reported incidence of second cancers.
Medical surveillance bias, for example, may have been responsible for the high rates of
second cancers of the prostate, kidney, and thyroid frequently seen in Connecticut
(Table 9). Interestingly, only patients with prostate cancer were at significantly low
risk for second cancer development; however, this might be an artifact ofcase-finding,
since advanced age at initial diagnosis was generally associated with an underascer-
tainment of second cancer. The frequency of autopsies also contributes to the number
of second cancers. For example, 1,280 second prostate cancers were observed overall
compared to 893 expected, but 316 of the 387 excess prostate cancers were identified
TABLE 9
Examples of Observed-to-Expected Ratios for Which the Risk of Second Cancers Might Be Related
to Increased (or Decreased) Medical Surveillance of Persons with an Initial Primary Cancer
No.
First Cancer Second Cancer Second Cancers RR*
Lung Prostate 121 2.0
Breast Thyroid 28 1.6
Prostate Esophagus 15 0.5
Stomach 61 0.7
Colon 174 0.9
Lung 182 0.7
Brain 2 0.2
*O/E ratios for second primaries withp < .05
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TABLE 10
Examples of Observed-to-Expected Ratios of Certain Cancers for Which the "Autopsy Only"
Diagnoses for the Second Cancer Were Responsible in Large Part for the Significance
of the Findings
No.
First Cancer Second Cancer Second Cancers RR*
Leukemia Prostate 41 1.7
Kidney 13 3.1
Bladder Prostate 236 1.6
Kidney Prostate 43 1.5
Kidney Bone 3 9.0
Stomach Kidney 12 2.2
Colon Kidney 48 1.4
Brain 13 1.9**
Esophagus Thyroid 2 17.2
*O/E ratios for second primaries withp < .05
**Females only
only on the basis of autopsy findings or death certificate reports. For some multiple
cancers such as those listed in Table 10, theautopsydiagnoses were responsible in large
part for the significance of the findings. The practice of radiation therapy has also
changed as supervoltage machines have replaced orthovoltage units, and different dose
distributions to organs receiving scatter radiation may alter the pattern of second
cancer occurrence. New therapies such as chemotherapy have been introduced and
affect the risk ofsome second cancers, most notably ANLL [28]. Some findings might
be influenced by changing coding classifications ofcancer and by misclassifications of
therapy in registry records. Finally, in any analysis which involves a large number of
comparisons, one can expect spurious associations to develop based on chance alone.
The special advantages of this survey, however, are the exceptionally large number
of subjects studied in a population-based cancer registry, the long follow-up available
(almost fifty years), and the strict criteria used by a single registry to record second
primary cancers. Thus, our survey ofmultiple primary cancers in Connecticut provides
investigators with a special opportunity to estimate risks and clarify constellations of
multiple cancer. A better understanding of multiple cancers should yield greater
insights into the risk factors and basic mechanisms of carcinogenesis and provide a
more sound basis for the management of cancer-prone individuals, including the
development ofprotective measures.
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